FAQ — Aureobasidium Beta Glucan

Aureobasidium pullulans beta glucan is a polysaccharide produced by black yeast (Aureobasidium pullulans) through controlled fermentation. It features β-1,3/1,6 glycosidic linkages that interact with immune receptors including Dectin-1 and complement receptor CR3.

Unlike oat or barley beta glucan (β-1,3/1,4), it requires no chemical extraction and retains its natural biological structure — making it distinct in both molecular architecture and immune-modulating activity.

Aureobasidium pullulans is a naturally occurring polymorphic black yeast found in soil, plant surfaces, and aquatic environments worldwide. It is not pathogenic in healthy individuals and is distinct from molds associated with infection.

In research and commercial settings, specific strains are cultivated under controlled fermentation conditions to produce high-purity beta glucan. The organism naturally secretes beta glucan as part of its cellular structure during growth.

The notation β-1,3/1,6 describes the molecular structure of the polysaccharide. It refers to:

β (beta): The stereochemical configuration of the glycosidic bond — important for how immune receptors recognize the molecule.

1,3: The primary backbone linkage — glucose units connected at the 1 and 3 carbon positions, forming the main chain.

1,6: Branch points — side chains attached at the 1 and 6 positions, creating the branching structure critical for Dectin-1 receptor binding.

This specific combination of backbone and branching is what distinguishes Aureobasidium beta glucan from oat beta glucan (β-1,3/1,4), which lacks the 1,6 branches.

No. Pullulan and beta glucan are two distinct polysaccharides produced by Aureobasidium pullulans.

Pullulan is a linear polysaccharide made of maltotriose units linked by α-1,6 bonds — widely used as a food additive and film-forming agent.

Beta glucan has β-1,3/1,6 linkages and is the immune-active compound studied for its effects on NK cells, macrophages, and antiviral/anti-tumor activity. They are produced by the same organism but are chemically and functionally different.

Beta glucan from Aureobasidium pullulans activates innate immunity through two primary receptor pathways:

Dectin-1 pathway: Binding to Dectin-1 on macrophages and dendritic cells triggers NF-κB signaling → cytokine production (TNF-α, IL-6, IL-12) → phagocytosis enhancement.

CR3 pathway: Binding to Complement Receptor 3 (CR3/CD11b) on NK cells primes them for enhanced cytotoxic activity against tumor cells and virus-infected cells.

Studies also document a Dectin-1 independent pathway involving interferon-stimulated gene (ISG) upregulation — providing additional antiviral immune activation. Research Archive

Dectin-1 (also known as CLEC7A) is a C-type lectin receptor expressed on the surface of macrophages, dendritic cells, monocytes, and neutrophils. It is a pattern recognition receptor (PRR) — part of the innate immune system’s ability to detect non-self molecular patterns.

Dectin-1 specifically recognizes β-1,3-glucan structures, which are found in fungal cell walls but not in mammalian cells. When Dectin-1 binds beta glucan, it triggers downstream signaling through Syk kinase and NF-κB, activating the cell’s antimicrobial and antitumor responses.

The branched β-1,3/1,6 structure of Aureobasidium beta glucan is particularly well-matched to Dectin-1 binding geometry. Molecular Interactions of β-Glucans with Their Receptors

Studies on macrophage stimulation with Aureobasidium pullulans beta glucan document production of the following cytokines:

Pro-inflammatory / immune-activating: TNF-α (tumor necrosis factor), IL-6 (interleukin-6), IL-12, IFN-γ (interferon-gamma).

Antiviral: Type I interferons (IFN-α/β) via ISG upregulation in the Dectin-1 independent pathway.

The specific cytokine profile varies by cell type, dose, and study conditions. Cytokine production is considered evidence of immune activation, not inflammation in the pathological sense. Stimulation of Macrophages with β-Glucan · Research Archive

Yes. Multiple animal and human studies use oral administration and document systemic immune effects — suggesting the beta glucan or its active metabolites reach immune cells beyond the gut.

A stable isotope tracer study using ²H-labeled beta glucan tracked intestinal absorption kinetics and detected labeled polysaccharide in peripheral blood — providing direct evidence that orally administered Aureobasidium beta glucan is absorbed. Probes for observation of intestinal post-absorptive kinetics · Research Archive

Additionally, gut-associated lymphoid tissue (GALT) may play a role, where beta glucan stimulates intestinal immune cells that then signal systemically.

The key differences are in molecular linkage, production method, and primary biological effects:

Linkage: Oat beta glucan is β-1,3/1,4. Aureobasidium beta glucan is β-1,3/1,6. The 1,6 branches are critical for Dectin-1 and CR3 receptor recognition. Oat beta glucan does not effectively bind these immune receptors.

Primary effect: Oat beta glucan is FDA-recognized for cholesterol reduction via viscosity in the gut. Aureobasidium beta glucan is studied primarily for immune activation (NK cells, macrophages) and antiviral/anti-tumor effects.

Production: Oat requires chemical or enzymatic extraction. Aureobasidium is produced through fermentation with no chemical solvents — native structure preserved.

Both mushroom beta glucan (from shiitake, maitake, reishi) and Aureobasidium beta glucan share the β-1,3/1,6 linkage structure and both activate Dectin-1. However, key differences exist:

Production: Mushroom beta glucan requires hot water or alcohol extraction from dried fruiting bodies. Aureobasidium is produced by yeast fermentation — a more controlled, scalable, and solvent-free process.

Purity and consistency: Fermentation-derived beta glucan offers higher batch-to-batch consistency compared to extraction from plant material, which varies by growing conditions, harvest time, and species.

Research volume: Mushroom beta glucans have more historical research. Aureobasidium-specific research has grown significantly in the past 20 years, with 188 studies now indexed.

Both are β-1,3/1,6 glucans from yeast sources, but with important differences:

Organism: Baker’s yeast (S. cerevisiae) is the source of most yeast-derived beta glucan supplements. Aureobasidium pullulans is a black yeast — taxonomically distinct with different fermentation characteristics.

Extraction: S. cerevisiae beta glucan typically requires acid or alkali extraction to remove cell wall proteins and lipids. Aureobasidium secretes beta glucan directly into the fermentation medium — no cell disruption or chemical treatment required.

Research specificity: Much early beta glucan research used S. cerevisiae-derived beta glucan. Aureobasidium-specific research has identified unique features including the Dectin-1 independent antiviral pathway not extensively documented in yeast glucan literature.

Multiple peer-reviewed safety studies have evaluated Aureobasidium pullulans beta glucan in animal models and human subjects. No significant adverse effects were reported at the tested doses across published studies.

Safety parameters typically evaluated include: liver function markers, kidney function, complete blood count, body weight, and organ histology. Published studies report no toxicological signals at standard doses.

Beta glucan activates innate immune responses — which is beneficial for most people but requires caution in those with autoimmune conditions (lupus, rheumatoid arthritis, MS, etc.) where the immune system is already overactive.

Published research has not specifically studied Aureobasidium beta glucan in autoimmune patient populations. The theoretical concern is that additional immune stimulation could exacerbate autoimmune activity.

No specific drug interaction studies have been published for Aureobasidium pullulans beta glucan. However, theoretical interactions may exist with:

Immunosuppressants: Beta glucan may reduce the efficacy of drugs designed to suppress immune function (e.g., cyclosporine, tacrolimus, corticosteroids).

Anticoagulants: Some polysaccharides can affect platelet aggregation — no specific data for Aureobasidium beta glucan, but caution is noted.

Chemotherapy: A Phase I-II clinical trial investigated beta glucan as an adjunct to chemotherapy — suggesting potential synergy rather than interference. Consult the treating oncologist. Phase I-II Trial · Research Archive

Aureobasidium pullulans is generally considered non-pathogenic in healthy, immunocompetent individuals. It is classified as a BSL-1 organism (Biosafety Level 1) — the lowest risk category.

Rare opportunistic infections have been reported in severely immunocompromised patients (e.g., transplant recipients on high-dose immunosuppression), but these are atypical. The organism is ubiquitous in the environment and most people are routinely exposed without incident.

Commercial beta glucan preparations use heat-sterilized fermentation broth — no viable organisms are present in the final product.

This site indexes 188 peer-reviewed studies on Aureobasidium pullulans beta glucan, spanning research from the 1980s to the present. The archive includes:

• RCTs (randomized controlled trials) and clinical studies
• In vivo (animal) studies
• In vitro (cell culture) studies
• Literature reviews
• Registered patents (Japan, EU, US, Taiwan, China, Hong Kong)

Research has been published in journals including Nutrients, Journal of Immunology, Carbohydrate Polymers, Antiviral Research, Atherosclerosis, and others. Browse the full archive →

Preclinical (in vitro and in vivo) studies demonstrate anti-tumor effects through:

• NK cell activation against tumor cells
• Dendritic cell stimulation enhancing T cell priming
• Synergy with PD-L1 checkpoint inhibitors (published 2022)
• Upregulation of Thrombospondin-1 (TSP-1), an endogenous tumor suppressor

A Phase I-II clinical trial evaluated beta glucan in patients with advanced malignancies receiving chemotherapy and documented safety and preliminary efficacy signals. Phase I-II Trial · Research Archive

Yes. Studies have investigated the antiviral potential of Aureobasidium pullulans beta glucan against respiratory viruses including influenza and SARS-CoV-2 (COVID-19). Key findings include:

• Significant upregulation of interferon-stimulated genes (ISGs) in macrophages
• Prevention of influenza-related mortality in animal models
• Immune modulation relevant to antiviral defense pathways

COVID-19 specific research is indexed in the Research Archive under the Antiviral topic. Studies suggest immune-priming effects rather than direct antiviral activity. Antiviral Topic Hub · Research Archive

Each study in our Research Archive includes:

• Full paper title and authors
• Journal name and publication year
• DOI link to the original paper (when available)
• PMID for direct PubMed lookup
• AI-generated summary covering background, method, key findings, and limitations

Papers without open access require institutional or personal journal subscriptions for full text. Abstracts are freely available via PubMed. Browse Research Archive →

Production involves five stages:

1. Strain selection: Specific Aureobasidium pullulans strains are selected for high beta glucan yield and consistent molecular structure.

2. Controlled fermentation: Cultures grown under regulated temperature, pH, and nutrient conditions. Fermentation parameters determine molecular weight and branching ratio.

3. Heat sterilization: The broth is heat-treated to eliminate viable organisms while preserving the polysaccharide structure. No acids, alkalis, or solvents are used.

4. Quality verification: Beta glucan concentration, molecular weight, and purity are confirmed by analysis.

5. Formulation: The resulting broth (containing beta glucan and fermentation co-products) is used as-is or further processed into powder or liquid forms.

The majority of peer-reviewed research on Aureobasidium pullulans beta glucan has been conducted at Japanese institutions, including Kitasato University, Hokkaido University, and Toray Research Center. Japan holds the largest patent portfolio for this compound (multiple patents registered since the 1990s).

Commercial production facilities operate in Japan. Research collaborations extend to institutions in the US, Europe, and Taiwan, as reflected in the patent registrations across multiple jurisdictions.

The production method directly affects the molecular structure of the final beta glucan, which determines how effectively it binds immune receptors.

Chemical extraction processes (acid, alkali, heat with solvents) can degrade or modify the β-1,3/1,6 branching structure — reducing Dectin-1 binding affinity and immunological potency.

Because Aureobasidium pullulans beta glucan is secreted directly into the fermentation medium and only heat-sterilized, the native triple-helix conformation and branching pattern associated with receptor recognition are preserved. Multiple studies cite the “high-purity, native-structure” characteristic as a differentiating factor in biological activity. Biological Activity of High-Purity β-1,3-1,6-Glucan · Research Archive